Our result suggested that thymoquinonein combination with TRAIL may be a therapeutic agent against MCF-7 and MDA-MB-231 breast cancer cells, which may be get attention in near future as a breakthrough in the treatment of breast cancer patients. The gene discussed is TNFSF10; the disease is breast carcinoma.